Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Jerini’s icatibant receives positive opinion in EU
The committee will now recommend that the European Commission grant marketing authorization for Icatibant, which is normally issued within 67 days from adoption of the Committee for Medicinal
The committee will now recommend that the European Commission grant marketing authorization for Icatibant, which is normally issued within 67 days from adoption of the Committee for Medicinal
Available as glucosamine hydrochloride and glucosamine sulphate, Osamine is said to bring forward high quality pharmaceutical grade glucosamine to the worldwide marketplace. Russ Anderson, president of Pharma Base
The controlling interest in Jiangsu Institute of Microbiology was acquired through two of Aida’s subsidiaries, namely Hangzhou Aida Pharmaceutical (which acquired a 43% equity interest) and Changzhou Fangyuan
The companies expect to report top-line results from this pivotal trial by July 2008 and submit a new drug application for Acurox tablets to the FDA before the
The 24 patient, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of LGD-4665 in adult patients with idiopathic thrombocytopenic purpura over six weeks of treatment.
In the 28-day trial, 30 patients with the hepatitis C virus (HCV) were enrolled to study the effects of MitoQ on elevated liver enzymes. Researchers measured patients’s baseline
Latona has entered into a licensing agreement to acquire the patent rights to Oralgam with Research Corporation Technologies. Under the terms of this agreement, Latona will acquire the
The study was designed to confirm an earlier proof of concept study. It is a ‘gold standard’ double-blind, placebo-controlled, multiple-dose crossover study comparing the efficacy of intra-vaginally delivered
The Sygnis research team has demonstrated in pre-clinical trials that AX200 counteracts the neuronal cell death and thereby decelerates the development of the disease. In the laboratory, protection
In his new role, Dr Finnegan will oversee the Phase III clinical program for Transdel’s lead product, Ketotransdel, a novel topical cream based non-steroidal anti-inflammatory drug for the